ES2559857T3 - Nuevos inhibidores de galactósido de galectinas - Google Patents

Nuevos inhibidores de galactósido de galectinas Download PDF

Info

Publication number
ES2559857T3
ES2559857T3 ES13700935.3T ES13700935T ES2559857T3 ES 2559857 T3 ES2559857 T3 ES 2559857T3 ES 13700935 T ES13700935 T ES 13700935T ES 2559857 T3 ES2559857 T3 ES 2559857T3
Authority
ES
Spain
Prior art keywords
optionally substituted
groups
group
independently selected
galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13700935.3T
Other languages
English (en)
Spanish (es)
Inventor
Ulf Nilsson
Hakon Leffler
Balaram Mukhopadhyay
Vishal Rajput
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galecto Biotech AB
Original Assignee
Galecto Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galecto Biotech AB filed Critical Galecto Biotech AB
Application granted granted Critical
Publication of ES2559857T3 publication Critical patent/ES2559857T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES13700935.3T 2012-01-25 2013-01-24 Nuevos inhibidores de galactósido de galectinas Active ES2559857T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12152413 2012-01-25
EP12152413.6A EP2620443A1 (en) 2012-01-25 2012-01-25 Novel galactoside inhibitors of galectins
PCT/EP2013/051339 WO2013110704A1 (en) 2012-01-25 2013-01-24 Novel galactoside inhibitors of galectins

Publications (1)

Publication Number Publication Date
ES2559857T3 true ES2559857T3 (es) 2016-02-16

Family

ID=47598867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13700935.3T Active ES2559857T3 (es) 2012-01-25 2013-01-24 Nuevos inhibidores de galactósido de galectinas

Country Status (8)

Country Link
US (1) US9353141B2 (enExample)
EP (2) EP2620443A1 (enExample)
JP (1) JP6158840B2 (enExample)
CN (1) CN104066743B (enExample)
CA (1) CA2854986C (enExample)
ES (1) ES2559857T3 (enExample)
IN (1) IN2014DN05772A (enExample)
WO (1) WO2013110704A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
IL149139A0 (en) 1999-11-03 2002-11-10 Bristol Myers Squibb Co Pharmaceutical compositions containing metformin and glyburide
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
WO2014078655A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
JP2016507503A (ja) 2012-12-20 2016-03-10 ヘンリー フォード ヘルス システム ガレクチン−3を阻害することによる拡張期心不全を治療する方法
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
EP3415522A1 (en) * 2014-07-09 2018-12-19 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
EP3828191A3 (en) * 2015-01-30 2021-08-18 Galecto Biotech AB Novel galactoside inhibitor of galectins
EP3423461A4 (en) * 2016-03-04 2020-03-25 Galectin Sciences, LLC SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THEIR USE
WO2018011094A1 (en) * 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
EP3484903A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE
WO2019133878A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CA3102155A1 (en) 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP3902797A1 (en) 2018-12-27 2021-11-03 GlycoMimetics, Inc. Galectin-3 inhibiting c-glycosides
JP7612663B2 (ja) * 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
CN116270672A (zh) * 2023-02-27 2023-06-23 江苏科技大学 β-D-硫代葡萄糖钠盐在制备缓解或治疗急性肾损伤的药物中的应用
CZ2023132A3 (cs) 2023-04-04 2024-10-16 Ústav Chemických Procesů Av Čr, V. V. I. Komplexy ruthenia pro inhibici galektinů, způsob jejich výroby a jejich použití

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
CN102066393B (zh) 2008-05-16 2014-07-02 格莱克特生物技术公司 半乳糖苷抑制剂的合成
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
ES2817888T3 (es) 2012-10-31 2021-04-08 Galecto Biotech Ab Inhibidor de galactósido de galectina-3 y su uso para tratar fibrosis pulmonar

Also Published As

Publication number Publication date
US20140336146A1 (en) 2014-11-13
CA2854986A1 (en) 2013-08-01
JP2015504909A (ja) 2015-02-16
CA2854986C (en) 2019-09-17
CN104066743A (zh) 2014-09-24
US9353141B2 (en) 2016-05-31
IN2014DN05772A (enExample) 2015-04-10
EP2620443A1 (en) 2013-07-31
EP2807176A1 (en) 2014-12-03
WO2013110704A1 (en) 2013-08-01
CN104066743B (zh) 2016-04-06
EP2807176B1 (en) 2015-12-30
JP6158840B2 (ja) 2017-07-05

Similar Documents

Publication Publication Date Title
ES2559857T3 (es) Nuevos inhibidores de galactósido de galectinas
CR20150447A (es) Nuevos derivados de pirazol
ECSP13013074A (es) Nuevos derivados de piridina
CR20150250A (es) Nuevos derivados de piridina
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20150204A (es) Nuevos derivados de piridina
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
UY35410A (es) Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
UY34414A (es) Composiciones hemostáticas
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP12012103A (es) Inhibidores de virus flaviviridae.
CR20150440A (es) Nuevos derivados de piridina
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
UY35447A (es) Moduladores de p2x7
UY34415A (es) Composiciones hemostáticas
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
UY35305A (es) Compuestos sustituidos como moduladores de la pro teína de activación de la 5-lipoxigenasa (flap)
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20150511A (es) Nuevos derivados de purina